A novel post-processing methodology able to assess whole-body tumor heterogeneity in patients with metastatic disease is proposed. The method is demonstrated on paired pre-and post-treatment data sets obtained from an initial cohort of six patients with metastatic disease from primary prostate or ovarian cancers. Whole-body diffusion-weighted imaging and T 1 -weighted contrast-enhanced imaging data were acquired covering the chest, abdomen, and pelvis. Joint histograms of Apparent Diffusion Coefficient and Fractional Enhancement values were calculated within volumes of interest and were modeled as a Gaussian mixture of two classes. Probability maps and volumetric estimates of the magnetic resonance data-derived classes providing visualization of pre-and post-treatment data are shown in three patient examples. This technique provided spatially heterogeneous characterization of regions following treatment as defined by the combined analysis of apparent diffusion coefficient and fractional enhancement. A new whole-body magnetic resonance data analysis has been demonstrated enabling visualization of intra-patient response heterogeneity in patients with metastatic cancer. Changes in the parameters of each subpopulation derived from this technique (apparent diffusion coefficient and fractional enhancement) reflect changes in the tissue properties of each subpopulation following treatment. Furthermore, the volume change of each population can be quantified. Such techniques may be essential for personalized anti-cancer therapy where there is a need to detect early drug-resistance and monitor heterogeneous response.
Introduction
Tumor heterogeneity relates to biological differences that may exist within and between tumors (intra-and inter-patient heterogeneity). [1] [2] [3] These differences arise as a result of clonal evolution in the genetic and micro-environmental characteristics of tumor-cell subpopulations, as the cancers grow and metastasize. [2] [3] [4] As oncologic practice evolves toward more precise and individualized therapy, consideration of tumor heterogeneity is gaining importance when assessing tumor response to treatment. 5, 6 More precise treatment targeting will rely on identification of the specific disease phenotype as undetected drug-resistant subclones can lead to disease that is unresponsive to treatment. Current practice utilizes surgical resection, sequential and/or multi-region biopsies to study and demonstrate tumor heterogeneity. However, these techniques are invasive, and biopsies are also prone to sampling bias, which may underestimate heterogeneity within and between tumors. 1, 7 Imaging techniques are non-invasive and can be performed in vivo at high-spatial resolution, making them ideal tools to study tumor heterogeneity, both prior to and during therapy. 8 Magnetic resonance imaging (MRI) is attractive as it does not incur ionizing radiation and can be safely repeated for sequential examinations. Furthermore, a range of functional imaging techniques (e.g. dynamic contrast-enhanced MRI [DCE-MRI], diffusion-weighted MRI [DWI] and intrinsic susceptibility MRI [IS-MRI]) can be applied to inform on biologically relevant tumor characteristics such as vascularity, cellularity and tissue oxygenation. In addition, recent MR system hardware developments have enabled extended imaging coverage over a wide area of the body within a clinically acceptable time frame, making it feasible to perform anatomical and functional whole-body MRI to evaluate patients with cancers involving both bones and soft tissues. [9] [10] [11] [12] The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop metastasis in bone. Bone biopsies are painful, not always accessible and are subject to sampling variation in regions of heterogeneity. Patients with metastatic ovarian carcinoma exhibit peritoneal and liver metastasis beyond the locally advanced disease in the pelvis.
In this manuscript, we propose a novel image analysis strategy for quantification and visualization of whole-body response heterogeneity in an exploratory cohort of six patients with metastatic ovarian and prostate cancers.
We focus our attention on the analysis of wholebody MRI examinations that combine DWI 11, 12 with a semi-quantitative T1-weighted contrast-enhanced imaging protocol. Both techniques provide voxel-wise quantification of the tumor microenvironment via coregistered calculation of the apparent diffusion coefficient (ADC) from DWI and the fractional enhancement (FE) from contrast-enhanced studies. Previous preclinical studies have demonstrated the correlation between increase in tumor ADC and cell-kill following successful treatment. 13 Furthermore, decrease in FE may reflect damage to the tumor vasculature.
14 By observing contemporaneous changes of these parameters by two-dimensional histogram analysis, we can visualize tumor response that conforms to the expected treatment behavior versus those areas that behave differently, thereby providing insights into response heterogeneity. We evaluate the ability of our new approach to identify clusters of voxels with defined characteristics, visualizing the spatial distributions in the body, and demonstrate the approach using paired pre-and post-treatment whole-body MRI data in six patients (a mix of responding and non-responding patients) following the same treatment with a noveltargeted agent. The analysis reported here is directed at exploring this newly proposed methodology for visualizing treatment effect.
Materials and methods Patients
Six patients with metastatic ovarian and castrate resistant prostate cancers enrolled in a phase II clinical trial testing, a novel targeted agent were reviewed before and after treatment. The whole cohort consisted of two women and four men, with age ranging from 48 to 70 years (mean age 64.2 years). All patients were scanned prior to and at six weeks after the start of treatment. In addition to their primary cancer location, patients had bone or liver metastases and nodal involvement.
All patients gave written informed consent, and the local ethical committee approved the research study.
Two patients (one ovarian and one prostate cancers) showed benefit from therapy as evidenced by clinical and biochemical parameters, while the remaining four patients demonstrated no significant benefit from therapy.
MR acquisition
All data were acquired on a 1.5T Avanto scanner (Siemens, Erlangen, Germany) using a neck coil plus two body-array coils to fully cover the chest, abdomen and pelvis of the patient. The MR protocol consisted of a sequential acquisition of three axial stations from chest to pelvis, repeated for each of the following sequences: (a) DWI, (b) T 1 -weighted pre-Gadolinium contrast administration, and (c) T 1 -weighted postGadolinium contrast (see Figure 1 ).
Diffusion sequence
DWI was performed during free-breathing using a twice refocused spin echo Inversion recovery 2D echo planar imaging with the following parameters: 46 contiguous slices per station, voxel resolution ¼ 2. A dose of contrast agent (Dotarem) of 0.2 ml/kg at 2 ml/s flow rate, followed by 20 ml of saline flush at the same flow rate, was delivered by power injector. The post contrast images were acquired at specific delayed time-points for each station following the first pass of contrast, i.e. 30 s (chest), 65 s (abdomen) and 120 s (pelvis) after injection (see Figure 1) . Following acquisition, the T 1 -weighted data were resampled to match the resolution of the DWI data using the OsiriX image-processing suite, 15 and a FE parameter map was calculated:
where S pre and S post are the signal intensities for the resampled pre-and post-contrast images, respectively. For further information on the effectiveness of using the FE parameter, please see the Appendix.
Image segmentation
Regions of interest were defined for disease by an experienced radiologist with five years of experience in body DW-MRI using computed high b-value images with the aid of a previously described segmentation technique. 16, 17 Briefly, the radiologist visually selected a computed b-value that maximized the contrast between disease and background tissues on Maximum Intensity Projection displays of the Whole-Body Diffusion-Weighted Imaging (WBDWI) data. An initial threshold was then manually selected to provide maximal contrast between disease and background classes by the expert reader. The classification was then smoothed using a Markov random field prior, after which the resulting tumor Volumes Of Interest (VOIs) ICR2 were manually corrected if necessary. Segmentation of patient data was performed before and after treatment by the same individual to avoid interoperator variation. All VOIs were stored and transferred onto calculated ADC and FE maps to enable voxel-wise statistics of ADC and FE to be recorded ( Figure 2(a) ).
Image analysis
Our aim was to segregate the derived joint distributions of ADC and FE into distinct subpopulations that may be biologically meaningful to reflect treatment response heterogeneity within and between tumors (i.e. cellularity as characterized by ADC and vascularity characterized by the FE values). For example, we expected viable tumors to return lower ADC values and higher FE values. The converse should be observed in responding treated tumors. We modeled joint histograms of ADC and FE of the total patient data set (i.e. pre-and posttreatment combined) using a Gaussian Mixture Model (GMM) of j ¼ 1 . . . M subpopulations, each of which may be characterized by a normal distribution N with mean vector m j and covariance matrix AE j . Given that a voxel i comes from subpopulation j, the probability of (2), and pelvis (3) for each sequence: DWI, T 1 -w pre-contrast, and T 1 -w post-contrast. The effect of the delay after Gadolinium administration on FE values estimated at each of the three stations was assessed visually by comparing FE distributions at each station individually (data not shown). The variation between stations was observed to be smaller than that between tissue populations, suggesting our results were not affected by these acquisition delays.
its value
where x i is a latent variable that defines the association of each voxel to a subpopulation. A typical prior for the latent variables consists of sets of weights, w j , for each subpopulation
with the following normalization constraint:
The marginalized probability of the values at each voxel is then given by
where a ¼ (w, m, AE) is a vector representing all model parameters. Fitting the parameter set using conventional estimation methods is complicated by the fact Figure 2 . Outline of image analysis steps (prostate patient, axial images). (a) Volumes of interest (VOIs -shown in green) are transferred from WBDWI data to the resolution-matched FE maps. (b) Co-registered FE and ADC voxels within the VOIs are visualized as a two-dimensional scatter plot. GMM is used to infer two subpopulations from the data (isocontours represent the logarithm of the fitted marginalized probability distribution, given by equation 6). The results from GMM fitting (c) may be used to calculate the classification probability of each voxel, visualized as a color scale overlaid on the DWI images for each visit (d).
that the latent variables, x i , are unknown. However, good estimation can be achieved using the Expectation-Maximization (EM) algorithm, an iterative optimization approach that attempts to maximize the likelihood of the Gaussian parameters, using the expected values for x i during each iteration. 18 After parameter fitting, it is then possible to derive the posterior classification probability of each voxel to a given subpopulation via Bayes' theorem and equations (3)- (5):
This classification can be visualized as a color scale to identify regions of heterogeneous tumor environment (see Figure 2) .
The image processing steps taken in our image analysis approach for quantification and visualization of response heterogeneity are demonstrated in Figure 2: (i) Pre-and post-contrast-enhanced images are interpolated to match the resolution and FoV of the DW-imaging studies using the OsiriX image-processing suite. 15 (ii) The interpolated data are used to calculate FE maps according to equation (2) , which are assumed to be inherently co-registered with the calculated ADC maps (this could be tested via visual inspection of fused post-contrast and low b-value images). Regions of interest defined on the DW-images are translated onto the FE maps (Figure 2(a) ). (iii) After visual inspection of the two dimension histogram, these data were modeled by a two-Gaussian Mixture (M ¼ 2) using the EM algorithm 
Results
The proposed methodology was successfully applied in all patient data sets; Table 1 presents the changes in ADC and FE for both of the sub-components in all patients, while Table 2 displays the changes in the proportional volume. Typical examples are demonstrated in Figures 3-5 . Figure 3 demonstrates the classification for a responding patient diagnosed with metastatic ovarian cancer (Patient 2). Before treatment, two components can clearly be seen; one color-coded red to represent regions of solid tumor (low ADC and highcontrast uptake indicated by high FE) and another color-coded green to represent regions of tumor lysis (indicated by an ADC close to that of free water and minimal contrast uptake). Following treatment, there is a 20.5% reduction in the proportional fluid volume in the tumor (see Table 2 ) suggesting clearance of this component, which is in agreement with an observed reduction of measured ADC (À0.59 Â 10 À3 mm 2 /s, Table 1 ). We also observed a reduction in the calculated FE for the viable tumor component (red) following treatment. This indicates degradation of the vascular network to the tumor in these regions, which is in line with the observed clinical response for this patient. Figure 4 presents an example of GMM analysis resolving two subpopulations before and after treatment for a prostate patient with bone disease and nodal involvement (Patient 4). One population demonstrates wide variation in FE and low ADC (red), suggestive of disease in this region. The second subpopulation demonstrated relatively wide variation in ADC and low FE values (green), indicating increased tumor necrosis and weaker vascular supply in these regions. Following treatment, we observed a reduction in the proportion of voxels within the first subpopulation and an increase in the proportion attributed to the second. Through the use of class probability maps ( Figure 4 , center column), it was demonstrated that this class-shift was mostly observed within the bone, while no significant changes were seen for the nodal site or prostate, clearly suggesting differential response for this patient.
In contrast, Figure 5 shows a prostate cancer patient (Patient 6) for which we observed little change in the measured values of ADC/FE (Table 1) or the tissue classification map, indicating non-responding, stable . GMM successfully resolves two subpopulations before and after treatment; one represented by areas of low ADC and higher FE (red), and another by areas of low FE and higher ADC (green). Before treatment, the majority of voxels belong to the red class, both in the bone and nodal sites. After treatment, we observed an increase in the proportion of voxels represented by the second class (green). This change was visualized to be primarily in the bone (center column), while no changes were seen for the nodal site or prostate. This was highly suggestive of differential response in this patient.
disease following therapy. Similar results were observed for three other patients, all of whom were classified as clinically not responding to treatment.
Discussion
Clonal evolution of cancer remains a major challenge for the successful management of patients using targeted and conventional therapies. 3, 19 The ability to accurately determine and distinguish regions that are responding versus those that are resistant to therapy would help to design better drug regimens, especially in patients who have had multiple lines of drug treatment since conventional size measurement criteria are often unhelpful assessing disease status in the presence of differential tumor response.
Imaging can provide non-invasive quantitative measurements to describe pathophysiological changes to the tumor in response to treatment. In this paper, we employed whole-body MRI combining DWI and contrast-enhanced imaging to quantify the tissue ADC and fractional tissue enhancement (FE), which are believed to reflect tumor cellularity and tumor vascularity, respectively. 13, 14 Through GMM of the joint distribution of voxel ADC and FE values in regions of suspect malignancy, we are able to classify biologically distinct sub-regions throughout the body and monitor changes to each sub-region both visually and quantitatively.
This technique was successfully applied to a small cohort of six patients, treated with a novel targeted therapy. In cases of metastatic bone cancer, it is not possible to monitor post-therapeutic tumor response using conventional size measurement criteria as bone metastases are considered 'unmeasurable'. 20 Our method provides not only quantification of biological changes occurring to bone as a result of treatment but also provides fully volumetric assessment of tumor burden, visualization and characterization of heterogeneous tumor response in vivo. Although previous studies have addressed the issue of tumor response heterogeneity through either single MR parameter methods (e.g. functional diffusion maps 21 ) or by multispectral analysis (MSA) of multi-parametric MRI, [22] [23] [24] these methods either relied on good registration of post-treatment data sets or were restricted to limited fields of view. Our technique provides whole-body estimation in a clinically feasible time frame and does not rely on accurate registration of pre-and post-treatment data sets.
In this paper, we have chosen to fit two subpopulations in the examples based on visual inspection of the multi-parametric histograms, and it should be noted that this may not be the general case. Other techniques such as non-parametric inference may be advantageous in this respect. 25 Furthermore, the cases presented in this paper are used to illustrate the potential of this technique, and future studies should include larger patient cohorts to validate this approach and explore the repeatability of the derived parameters. A caveat of our proposed technique is the assumption of good registration between the T 1 -w and DWI acquisitions, which may be problematic in regions that are subject to substantial respiratory motion such as the liver, which was excluded in the current study. However, given the large number of voxels available to wholebody MRI, we believe that motion will have minimal impact on the final results, especially when evaluating skeletal disease, which is static.
In conclusion, we describe a new multi-modal image processing methodology that can be used to provide quantification and visualization of the heterogeneity of tumors across the body and can be applied to both skeletal and soft tissue disease. Changes in the ADC and FE values inferred from MR imaging may reflect biological changes occurring in the tissue subpopulations following therapy. The volume change of each subpopulation can also be quantified providing clinicians with a treatment response biomarker that takes account of spatial heterogeneity. Understanding response heterogeneity is increasingly important in the development of more precise and personalized targeted cancer therapy. The methods described in this article could be easily be extended to incorporate other imaging modalities such as PET/CT (provided adequate spatial alignment of data sets can be achieved) equipping oncologists with new metrics for monitoring the response of patients to targeted therapies.
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where the presence of the contrast agent changes the longitudinal relaxation time of the tissue according to the relationship
r 1 4 0 is the constant relaxivity of the CA, as measured by the suppliers. Note that such two-point measurements do not provide full quantification of the CA concentration (there are three unknowns, R 1 , ÁR 1 and S 0 ). Instead, we define measures of signal enhancement that provide equivalent detail. Two such measures include the relative enhancement ( R ) and the fractional enhancement ( F ):
both of which are independent of S 0 . Two important requirements for these quantitative parameters is that they be monotonically increasing with increasing (CA) (or equivalently ÁR 1 ) and that they be well behaved in the presence of image noise. Demonstrated in Figure A1 are plots of R and F for ranges of biologically relevant CA concentrations and tissue relaxation times, T1. The flip angle and repetition time matched those of our clinical protocol ( ¼ 24 , TR ¼ 5.63 ms). It is clear that for the range of values explored in this diagram, both indices are monotonically increasing with increasing CA concentration. However, in this case, the relative enhancement provides a smoother response to changes in concentration and is more uniform over varying tissue relaxivities. A more universal approach to demonstrate monotonicity is to show that
or equivalently:
for all values of R 1 4 0 and ÁR 1 4 0. In the following two sections, we first prove that these inequalities hold for both the relative enhancement and fractional enhancement indices and then explore the statistical properties of these indices in the presence of image noise. We demonstrate that the fractional enhancement is less sensitive to noise due to its restriction within the range F 5 1 for S 1 4 0 and S 2 ! S 1 .
Proof of monotonicity for relative enhancement. By substituting (1) and (2) into (4): Figure A1 . Values of relative enhancement (left) and fractional enhancement (right) over a range of contrast agent concentrations and T1 values (color encoded). These figures demonstrate that both quantities are monotonically increasing with increasing concentration, although relative enhancement provides smoother changes.
Therefore,
Proof of monotonicity for fractional enhancement. By substituting equation (1) and (2) into (5) both enhancement fraction indices may be demonstrated graphically by introducing noise samples from a Rician distribution to S 1 and S 2 prior to calculation of Figure A1 . The results of these simulations are presented in Figure A2 for six potential values for the signal-to-noise ratio (SNR) of the S 0 image, where samples are generated by S 0 1 $ RiceðS 1 , 1=SNRÞ and S 0 2 $ RiceðS 2 , 1=SNRÞ. It is clear from these illustrations that the presence of noise has greater impact on the interpretation of the relative enhancement: In the cases where SNR ¼ 20 and SNR ¼ 50, the presence of outliers makes it difficult to distinguish between tissues with different T1 values, and results in a loss of the desired monistically increasing nature of the parameter. The fractional enhancement, however, retains the desired form and so we preferentially use this parameter for WBDCE analysis.
